Genetic testing for breast cancer predisposition.

[1]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[2]  A. Aurias,et al.  Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families , 1999, British Journal of Cancer.

[3]  P. Hartge,et al.  Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[4]  D. Stoppa-Lyonnet,et al.  Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. , 1999, Cancer research.

[5]  D. Berry,et al.  Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. , 1998, Journal of the National Cancer Institute.

[6]  J. Chang-Claude,et al.  Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. , 1998, European journal of cancer.

[7]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[8]  D. Stoppa-Lyonnet,et al.  Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Asselain,et al.  Survival in early-onset BRCA1 breast-cancer patients , 1998, The Lancet.

[10]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[11]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Birnbaum,et al.  Mutations at BRCA1: the medullary breast carcinoma revisited. , 1998, Cancer research.

[14]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[15]  Hongbing Zhang,et al.  BRCA1, BRCA2, and DNA Damage Response: Collision or Collusion? , 1998, Cell.

[16]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[17]  H. Lynch,et al.  Prognosis of BRCA1 hereditary breast cancer , 1998, The Lancet.

[18]  L. Bégin,et al.  Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[20]  W. Neufeld-Kaiser,et al.  Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. , 1997, JAMA.

[21]  M N Pollak,et al.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.

[22]  D. Easton.  Breast cancer genes—what are the real risks? , 1997, Nature Genetics.

[23]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[24]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[25]  P. Laurent-Puig,et al.  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. , 1997, American journal of human genetics.

[26]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[27]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[28]  K Offit,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. , 1997, JAMA.

[29]  E. Thomson,et al.  Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .

[30]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[31]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[32]  G. Lenoir,et al.  A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. , 1997, Cancer research.

[33]  P. Schlag,et al.  Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families , 1997, Oncogene.

[34]  J. Mornon,et al.  From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair , 1997, FEBS letters.

[35]  M. Swift,et al.  Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. , 1996, Cancer genetics and cytogenetics.

[36]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[37]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[38]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.

[39]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[40]  L. Cannon-Albright,et al.  Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.

[41]  D. Clayton,et al.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation , 1995, Nature Genetics.

[42]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[43]  D. Birnbaum,et al.  Histoprognostic grade in BRCA1-associated breast cancer , 1995, The Lancet.

[44]  L. Essioux,et al.  Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. , 1995, Oncogene.

[45]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[46]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[47]  K. Offit,et al.  Quantitating familial cancer risk: a resource for clinical oncologists. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[49]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[50]  C. Steel,et al.  Breast cancer survival in BRCA1 carriers , 1993, The Lancet.

[51]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[52]  S. Friend,et al.  Screening for germ line TP53 mutations in breast cancer patients. , 1992, Cancer research.

[53]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[54]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[55]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[56]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[57]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[58]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[59]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[60]  F. Arwert,et al.  The Cowden syndrome: a clinical and genetic study in 21 patients , 1986, Clinical genetics.

[61]  D. Stoppa-Lyonnet,et al.  An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? , 1999, American journal of human genetics.

[62]  M. J. Kahn,et al.  Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. , 1997, JAMA.

[63]  F. Couch,et al.  Mutations and Polymorphisms in the familial early‐onset breast cancer (BRCA1) gene , 1996, Human mutation.

[64]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[65]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .

[66]  K. Lloyd,et al.  Cowden's disease. A possible new symptom complex with multiple system involvement. , 1963 .